Lilly releases post-mortem data for the migraine drug Emgality Phase III clinical program

migraine is the second most disabled cause in the United States and can seriously affect the lives of patientsEmgality treatment can effectively reduce the number of days of migraine attacks per monthGiven the disabilities and functional limitations caused by migraines, it is important thatdrug(http:// such as Emgalitytreatment improve soutcomes associated with migraines and limits on daily activities, relationships, productivity, and free timeAt the american headache society's 61st annual scientificconference(http://, Lilly recently released post-mortemanalysisdatahttp:// from the critical phase III clinical program of the migraine drug Emgality-gnlmThe results showed that emgality therapy improved the daily function and delayed the progression of disability in patients with chronic migraines and seizure migrainesAbout Emgality
Emgality is a monoclonal antibody that selectively binds to calcitonin gene-related peptides (CGRP)CGRP is a neuropeptide that has been shown to be released during a migraine attack and is thought to be a trigger for a migraine attackAt present, CGRP and its receptors have become a hot target for the development of migraine drugsIn the United States and the European Union, Emgality was approved in September and November 2018 for the prevention of migraines in adult patientsIn June, Emgality was approved by the U.SFDA(http://to treat adult seizure cluster headaches (ECH) to reduce the frequency of seizuresThe approval makes Emgality the first and only drug to treat ECH, the first and only CGRP antibody drug approved by the FDA for two different headache disordersTo date, three antibody-like migraine drugs targeting CGRP and its receptors have been available, and the other two are Novartis/Amgen Aimovig and Teva AjovyOf these, Emgality and Aimovig were given a monthly subcutaneous injection, while Ajovy had a monthly or tri-monthly subcutaneous injectionIn addition, the(http://of theof The Alderhas been reviewed in the United States, where the drug is intravenously administered every three months